A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Isoquercetin on Thromboembolic Events in Patients with Metastatic Pancreatic Cancer (CATIQ P3)

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Isoquercetin (Primary)
Indications Adenocarcinoma; Pancreatic cancer; Venous thromboembolism
Focus Registrational; Therapeutic Use
Acronyms CATIQ P3
Sponsors Quercis Pharma

Most Recent Events

08 Mar 2025 Status changed from planning to not yet recruiting.
04 May 2021 According to a Quercis Pharma media release, the company has entered into a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA).Study start-up activities already under way, and the company looks forward to initiating this Phase 3 study.
29 Jan 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight